Sowell Financial Services LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 13,849 shares of the biopharmaceutical company’s stock after selling 5,804 shares during the period. Sowell Financial Services LLC’s holdings in Gilead Sciences were worth $807,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of GILD. MUFG Securities EMEA plc boosted its stake in shares of Gilead Sciences by 9.3% during the 3rd quarter. MUFG Securities EMEA plc now owns 718,000 shares of the biopharmaceutical company’s stock worth $45,370,000 after buying an additional 60,829 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Gilead Sciences by 365.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 80,998 shares of the biopharmaceutical company’s stock worth $5,118,000 after acquiring an additional 63,588 shares in the last quarter. First Financial Bank Trust Division boosted its position in Gilead Sciences by 0.9% in the fourth quarter. First Financial Bank Trust Division now owns 98,154 shares of the biopharmaceutical company’s stock valued at $5,719,000 after buying an additional 873 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in Gilead Sciences in the third quarter valued at approximately $29,037,000. Finally, Transcend Wealth Collective LLC boosted its position in Gilead Sciences by 29.6% in the third quarter. Transcend Wealth Collective LLC now owns 20,265 shares of the biopharmaceutical company’s stock valued at $1,281,000 after buying an additional 4,627 shares in the last quarter. Institutional investors own 76.36% of the company’s stock.
GILD has been the subject of several analyst reports. Guggenheim raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research note on Monday, January 4th. Oppenheimer decreased their price target on shares of Gilead Sciences from $105.00 to $100.00 and set an “outperform” rating for the company in a research note on Thursday, December 17th. SVB Leerink reduced their price objective on shares of Gilead Sciences from $88.00 to $79.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. Robert W. Baird boosted their price target on shares of Gilead Sciences from $63.00 to $67.00 and gave the stock a “neutral” rating in a report on Wednesday, December 16th. Finally, Barclays cut their price target on shares of Gilead Sciences from $67.00 to $62.00 in a report on Thursday, October 29th. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eleven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $92.87.
Gilead Sciences stock opened at $63.33 on Friday. The company has a debt-to-equity ratio of 1.65, a current ratio of 3.25 and a quick ratio of 3.15. Gilead Sciences, Inc. has a 1-year low of $56.56 and a 1-year high of $85.97. The company has a market cap of $79.39 billion, a PE ratio of 10.26, a price-to-earnings-growth ratio of 0.67 and a beta of 0.51. The stock’s 50 day moving average price is $59.96 and its 200 day moving average price is $64.67.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, October 28th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.90 by $0.21. The company had revenue of $6.58 billion during the quarter, compared to analysts’ expectations of $6.20 billion. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.06 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th were given a $0.68 dividend. This represents a $2.72 annualized dividend and a dividend yield of 4.29%. The ex-dividend date was Monday, December 14th. Gilead Sciences’s payout ratio is 44.30%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.